Entry into a Material Definitive Agreement

Business Context and Reporting Period

Company: Ekso Bionics Holdings, Inc. (Note: Input metadata referenced "Chronoscale Holdings Corp," but the filing text identifies the registrant as Ekso Bionics Holdings, Inc.)
Filing Type: Form 8-K (Current Report)
Date: January 30, 2019
Context: The Company entered into material definitive agreements to establish a joint venture in China and secure financing.

Key Financial Metrics and Transaction Details

Financing Transaction:

  • Shares Issued: 3,067,485 shares of common stock.
  • Price Per Share: $1.63 (closing price on January 29, 2019).
  • Total Proceeds: Approximately $5,000,000.
  • Future Investment: An additional $5,000,000 investment is contingent upon the Joint Venture delivering its first batch of EksoGT products. The price for this tranche will be the 20-day VWAP, with a floor of $1.30 and a cap of $1.96.
Joint Venture (JV) Capitalization:
  • Entity: Exoskeleton Intelligent Robotics Co. Limited.
  • Ownership Structure: Zhejiang Youchuang Venture Capital Investment Co., Ltd. (41.54%), Industrial Investment Fund (38.46%), Ekso US (20.00%).
  • Capital Contributions: JV Partners to contribute RMB 624 million cash; Ekso US to contribute patents valued at RMB 145 million.
Revenue and Profit: The filing does not provide specific revenue, profit, cash flow, or margin figures for the reporting period.

Material Changes and Strategic Developments

Joint Venture Establishment:

  • Objective: Develop and serve the exoskeleton market in China and select Asian markets (excluding Japan, India, and Australia) and create a global manufacturing center.
  • Products: Manufacturing of EksoGT, EksoVest, and EksoZeroG Arm units.
  • Revenue Model: Ekso US will receive a royalty fee based on a mid-single-digit percentage of net sales revenue from JV products.
  • Licensing: Ekso US granted the JV an exclusive, irrevocable license to use patented and non-patented technologies and trademarks in the JV Territory.
Antidilution Provision:
  • If the Company sells shares below $1.63 within 60 days, Purchasers are entitled to additional shares to maintain an aggregate purchase price of $5,000,000 at the lower price, capped at 19.9% of total outstanding shares.

Guidance, Risks, and Contingencies

Management Commentary: The filing focuses on the execution of the JV and financing agreements to expand manufacturing and market presence in Asia.
Risks and Contingencies:

  • Regulatory Compliance: The financing relies on Regulation S exemption; Purchasers represented they are not U.S. persons.
  • Future Funding: The second tranche of $5,000,000 is contingent on the successful delivery of the first batch of finished EksoGT products by the Joint Venture.
  • Dilution: The antidilution provision could result in additional share issuance if the stock price drops below $1.63 within 60 days.
Unusual Items: None reported beyond the standard terms of the JV and financing agreements.

Investor Verification Checklist

  • Verify the final closing of the $5,000,000 initial financing and the issuance of 3,067,485 shares.
  • Monitor the stock price over the next 60 days to assess potential dilution under the antidilution provision.
  • Confirm the formation of the Joint Venture and the receipt of the initial 30% cash contribution (RMB 187.2 million) from JV Partners.
  • Track the timeline for the delivery of the first batch of EksoGT products to trigger the second $5,000,000 investment tranche.
  • Review the full text of the JV Agreement and Purchase Agreement when filed as exhibits to the Form 10-Q for the period ending March 31, 2019.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.